Ameti Adelina, Kopp Peter A, Pitteloud Nelly, Wuerzner Grégoire, Grouzmann Eric, Matter Maurice, Lamine Faiza, Phan Olivier
Division of Endocrinology, Diabetes & Metabolism, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.
Division of Nephrology and Hypertension, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.
AACE Clin Case Rep. 2024 Apr 13;10(4):136-139. doi: 10.1016/j.aace.2024.04.001. eCollection 2024 Jul-Aug.
Due to the high prevalence of hypertension in patients with autosomal dominant polycystic kidney disease (ADPKD) and advanced chronic kidney disease, diagnosing secondary hypertension poses challenges. We present a rare case of pheochromocytoma in an ADPKD patient to highlight the diagnostic difficulties in identifying secondary hypertension due to pheochromocytoma/paraganglioma (PPGL) in end-stage renal disease (ESRD) patients.
A 48-year-old female with ADPKD and ESRD experienced recurrent hypertensive crises (up to 220/135 mmHg) accompanied by palpitations and tremors that recurred over the past 2 years. Introduction of a betablocker to the antihypertensive therapy aggravated her symptoms. The initial documentation of elevated urinary metanephrines was interpreted as false positive finding due to renal failure. Subsequent measurements of free plasma metanephrines revealed significant elevations raising suspicion of PPGL. Magnetic resonance imaging identified a 29 mm right adrenal mass. The patient underwent right adrenalectomy resulting in resolution of the hypertensive crises.
The diagnosis of PPGLs can present significant challenges and is further complicated in ESRD due to nonspecific clinical symptoms and diagnostic pitfalls. Less than 20 PPGL cases have been reported in patients with ESRD. The intolerance of beta-blocker therapy, as well as the use of a scoring system for the likelihood of PPGL should have raised suspicion.
PPGL should be considered in all patients with uncontrolled hypertension and beta-blockers intolerance, even in the presence of other etiologic mechanisms such as ESRD. Measuring free plasma metanephrines provides the most reliable biochemical screening in the context of impaired renal function.
由于常染色体显性多囊肾病(ADPKD)患者和晚期慢性肾病患者中高血压的高患病率,诊断继发性高血压具有挑战性。我们报告一例ADPKD患者发生嗜铬细胞瘤的罕见病例,以突出在终末期肾病(ESRD)患者中识别由嗜铬细胞瘤/副神经节瘤(PPGL)引起的继发性高血压的诊断困难。
一名48岁患有ADPKD和ESRD的女性在过去2年中经历了反复的高血压危象(高达220/135 mmHg),伴有心悸和震颤。在抗高血压治疗中加用β受体阻滞剂使她的症状加重。最初尿间甲肾上腺素升高的记录被解释为由于肾衰竭导致的假阳性结果。随后游离血浆间甲肾上腺素的测量显示显著升高,这引起了对PPGL的怀疑。磁共振成像发现右侧肾上腺有一个29 mm的肿块。患者接受了右侧肾上腺切除术,高血压危象得以缓解。
PPGL的诊断可能面临重大挑战,在ESRD患者中由于非特异性临床症状和诊断陷阱而更加复杂。在ESRD患者中报道的PPGL病例少于20例。β受体阻滞剂治疗不耐受以及使用PPGL可能性的评分系统本应引起怀疑。
对于所有高血压控制不佳且对β受体阻滞剂不耐受的患者,即使存在其他病因机制如ESRD,也应考虑PPGL。在肾功能受损的情况下,测量游离血浆间甲肾上腺素可提供最可靠的生化筛查。